five

An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects

收藏
DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/PR00007831/isLanding
下载链接
链接失效反馈
官方服务:
资源简介:
This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease activity. Rebound phenomenon will be assessed for subjects who have permanently withdrawn from further belimumab treatment.
提供机构:
Vivli
创建时间:
2022-04-25
二维码
社区交流群
二维码
科研交流群
商业服务